Clinical Trials
10 trialsNCT00003398 2019-10-17
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
Phase 4 Completed
NCT00005092 2018-10-26
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00245115 2018-08-23
Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT00555048 2017-05-24
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT01020734 2015-12-31
Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Asan Medical Center
Phase 2 Completed
NCT00002547 2012-08-07
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00004896 2012-06-12
Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Northwestern University
Phase 2 Completed
NCT00002945 2012-04-13
High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 3 Completed
NCT01177371 2010-08-09
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00293410 2010-05-06
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed